NCT06325683 2026-03-18
Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
4 trialsNCT04863950 2025-08-27
Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Phase 2 Recruiting
NCT06177964 2025-08-17
Lerapolturev (PVSRIPO) in GBM
Duke University
Phase 2 Recruiting
NCT06336291 2025-01-24
GLIOSTELLA
Philogen S.p.A.
Phase 2 Recruiting